- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01245062
GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Contacten en locaties
Studie Locaties
-
-
-
Ciudad Autonoma de Buenos Aires, Argentinië, C1121ABE
- GSK Investigational Site
-
-
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australië, 2606
- GSK Investigational Site
-
-
New South Wales
-
Port Macquarie, New South Wales, Australië, 2444
- GSK Investigational Site
-
Waratah, New South Wales, Australië, 2300
- GSK Investigational Site
-
-
Queensland
-
South Brisbane, Queensland, Australië, 4101
- GSK Investigational Site
-
Townsville, Queensland, Australië, 4810
- GSK Investigational Site
-
Woolloongabba, Queensland, Australië, 4102
- GSK Investigational Site
-
-
South Australia
-
Kurralta Park, South Australia, Australië, 5037
- GSK Investigational Site
-
Woodville, South Australia, Australië, 5011
- GSK Investigational Site
-
-
Victoria
-
Heidelberg, Victoria, Australië, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australië, 3004
- GSK Investigational Site
-
-
-
-
-
Brussels, België, 1200
- GSK Investigational Site
-
Charleroi, België, 6000
- GSK Investigational Site
-
Gent, België, 9000
- GSK Investigational Site
-
Jette, België, 1090
- GSK Investigational Site
-
Kortrijk, België, 8500
- GSK Investigational Site
-
Leuven, België, 3000
- GSK Investigational Site
-
Wilrijk, België, 2610
- GSK Investigational Site
-
Yvoir, België, 5530
- GSK Investigational Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- GSK Investigational Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- GSK Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- GSK Investigational Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- GSK Investigational Site
-
London, Ontario, Canada, N6A 4L6
- GSK Investigational Site
-
Oshawa, Ontario, Canada, L1G 2B9
- GSK Investigational Site
-
Ottawa, Ontario, Canada, K1H 8L6
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5G 2M9
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 4M1
- GSK Investigational Site
-
Montreal, Quebec, Canada, H2W 1S6
- GSK Investigational Site
-
-
-
-
-
Berlin, Duitsland, 10117
- GSK Investigational Site
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Duitsland, 69120
- GSK Investigational Site
-
Mannheim, Baden-Wuerttemberg, Duitsland, 68167
- GSK Investigational Site
-
Tuebingen, Baden-Wuerttemberg, Duitsland, 72076
- GSK Investigational Site
-
-
Bayern
-
Muenchen, Bayern, Duitsland, 80804
- GSK Investigational Site
-
Wuerzburg, Bayern, Duitsland, 97080
- GSK Investigational Site
-
-
Niedersachsen
-
Buxtehude, Niedersachsen, Duitsland, 21614
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Essen, Nordrhein-Westfalen, Duitsland, 45122
- GSK Investigational Site
-
-
Sachsen
-
Dresden, Sachsen, Duitsland, 01307
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Luebeck, Schleswig-Holstein, Duitsland, 23538
- GSK Investigational Site
-
-
-
-
-
Boulogne-Billancourt, Frankrijk, 92100
- GSK Investigational Site
-
Grenoble, Frankrijk, 38043
- GSK Investigational Site
-
Montpellier, Frankrijk, 34295
- GSK Investigational Site
-
Nantes, Frankrijk, 44093
- GSK Investigational Site
-
Paris Cedex 10, Frankrijk, 75475
- GSK Investigational Site
-
Pierre-Benite cedex, Frankrijk, 69495
- GSK Investigational Site
-
Rennes, Frankrijk, 35042
- GSK Investigational Site
-
Tours, Frankrijk, 37044
- GSK Investigational Site
-
Villejuif, Frankrijk, 94805
- GSK Investigational Site
-
-
-
-
-
Athens, Griekenland, 11527
- GSK Investigational Site
-
Athens, Griekenland, 185 47
- GSK Investigational Site
-
Thessaloniki, Griekenland, 564 29
- GSK Investigational Site
-
-
-
-
Lombardia
-
Milano, Lombardia, Italië, 20132
- GSK Investigational Site
-
Milano, Lombardia, Italië, 20133
- GSK Investigational Site
-
Milano, Lombardia, Italië, 20141
- GSK Investigational Site
-
-
Toscana
-
Pisa, Toscana, Italië, 56126
- GSK Investigational Site
-
-
-
-
-
Christchurch, Nieuw-Zeeland, 8011
- GSK Investigational Site
-
Dunedin, Nieuw-Zeeland, 9016
- GSK Investigational Site
-
Newtown, Wellington, Nieuw-Zeeland, 6002
- GSK Investigational Site
-
-
-
-
-
Oslo, Noorwegen, 0310
- GSK Investigational Site
-
-
-
-
-
Dnepropetrovsk, Oekraïne, 49102
- GSK Investigational Site
-
Kharkiv, Oekraïne, 61070
- GSK Investigational Site
-
Kyiv, Oekraïne, 03022
- GSK Investigational Site
-
Kyiv, Oekraïne, 03115
- GSK Investigational Site
-
Lviv, Oekraïne, 79031
- GSK Investigational Site
-
Sumy, Oekraïne, 40005
- GSK Investigational Site
-
Sympheropol, Oekraïne, 95023
- GSK Investigational Site
-
Ternopil, Oekraïne, 46023
- GSK Investigational Site
-
Uzhgorod, Oekraïne, 88017
- GSK Investigational Site
-
-
-
-
-
Graz, Oostenrijk, 8036
- GSK Investigational Site
-
Wien, Oostenrijk, 1090
- GSK Investigational Site
-
-
-
-
-
Poznan, Polen, 61-866
- GSK Investigational Site
-
Warszawa, Polen, 02-781
- GSK Investigational Site
-
Warszawa, Polen, 04-125
- GSK Investigational Site
-
-
-
-
-
Chelyabinsk, Russische Federatie, 454087
- GSK Investigational Site
-
Magnitogorsk, Russische Federatie, 455001
- GSK Investigational Site
-
Moscow, Russische Federatie, 115478
- GSK Investigational Site
-
St. Petersburg, Russische Federatie, 197758
- GSK Investigational Site
-
-
-
-
-
Hradec Kralove, Tsjechië, 500 05
- GSK Investigational Site
-
Ostrava, Tsjechië, 708 52
- GSK Investigational Site
-
Praha 2, Tsjechië, 128 08
- GSK Investigational Site
-
Zlin, Tsjechië, 76275
- GSK Investigational Site
-
-
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- GSK Investigational Site
-
Birmingham, Verenigd Koninkrijk, B15 2TH
- GSK Investigational Site
-
Chelmsford, Verenigd Koninkrijk, CM1 7ET
- GSK Investigational Site
-
Leeds, Verenigd Koninkrijk, LS9 7TF
- GSK Investigational Site
-
London, Verenigd Koninkrijk, SW3 6JJ
- GSK Investigational Site
-
London, Verenigd Koninkrijk, W1G 6AD
- GSK Investigational Site
-
Manchester, Verenigd Koninkrijk, M20 4BX
- GSK Investigational Site
-
Oxford, Verenigd Koninkrijk, OX3 7LJ
- GSK Investigational Site
-
Southampton, Verenigd Koninkrijk, SO16 6YD
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Verenigd Koninkrijk, CB2 2QQ
- GSK Investigational Site
-
-
Middlesex
-
Northwood, Middlesex, Verenigd Koninkrijk, HA6 2RN
- GSK Investigational Site
-
-
Surrey
-
Sutton, Surrey, Verenigd Koninkrijk, SM2 5PT
- GSK Investigational Site
-
-
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85724-5024
- GSK Investigational Site
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33916
- GSK Investigational Site
-
-
Georgia
-
Athens, Georgia, Verenigde Staten, 30607
- GSK Investigational Site
-
Marietta, Georgia, Verenigde Staten, 30060
- GSK Investigational Site
-
-
Iowa
-
Iowa City, Iowa, Verenigde Staten, 52242
- GSK Investigational Site
-
-
Louisiana
-
Metairie, Louisiana, Verenigde Staten, 70006
- GSK Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- GSK Investigational Site
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07962-1956
- GSK Investigational Site
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- GSK Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29210
- GSK Investigational Site
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- GSK Investigational Site
-
Memphis, Tennessee, Verenigde Staten, 38120
- GSK Investigational Site
-
Nashville, Tennessee, Verenigde Staten, 37203
- GSK Investigational Site
-
-
-
-
-
Goteborg, Zweden, SE-413 45
- GSK Investigational Site
-
Linkoping, Zweden, SE-581 85
- GSK Investigational Site
-
Lund, Zweden, SE-221 85
- GSK Investigational Site
-
Stockholm, Zweden, SE-171 76
- GSK Investigational Site
-
Uppsala, Zweden, SE-751 85
- GSK Investigational Site
-
-
-
-
-
Zurich, Zwitserland, 8091
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- ≥18 years of age
- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
- Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Adequate screening organ function
Exclusion Criteria:
- Any prior use of BRAF inhibitors or MEK inhibitors.
- Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
- History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
- Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor:
All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization
History or evidence of cardiovascular risk including any of the following:
- QTcB ≥ 480 msec.
- History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible
- History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization.
- History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
- History of interstitial lung disease or pneumonitis
History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR):
- History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes).
- Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
- Evidence of new optic disc cupping.
- Intraocular pressure > 21 mm Hg as measured by tonography
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: GSK1120212
MEK inhibitor
|
MEK-remmer
|
Actieve vergelijker: Chemotherapy
Investigator Choice of DTIC or paclitaxel
|
Investigator Choice of DTIC or paclitaxel
|
Experimenteel: Crossover
MEK inhibitor after documented progression on Chemotherapy Arm
|
MEK-remmer
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Progression-free survival (PFS) is defined as the time from randomization to the first documented occurrence of disease progression (PD) or death.
PFS for investigator-assessed and blinded, independent, central review committee (BRIC)-assessed responses was summarized per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1, which is a set of published rules defining when cancer participants improve (respond), stay the same (stabilize), or worsen (progress) during treatment.
Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Primary Efficacy Population included all participants with BRAF V600E mutation-positive melanoma without a history of brain metastases.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Progression-free Survival in All Participants
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed and BRIC-assessed PFS were summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
Intend-To-Treat (ITT) Population included all randomized participants regardless of whether or not treatment was administered.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and Without Prior Chemotherapy as Assessed by the Investigator
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases and With Prior Chemotherapy as Assessed by the Investigator
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
PFS is defined as the time from the date of randomization to the first documented occurrence of PD or death.
Investigator-assessed PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Overall Survival in All Participants
Tijdsspanne: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Overall Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases
Tijdsspanne: Day 1 until death due to any cause (average of 20.3 months)
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause.
NA indicates data was not available.
|
Day 1 until death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Without a History of Brain Metastases With Overall Response (OR) as Assessed by the Investigator and Independent Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR as Assessed by the Investigator and Independent Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator and an independent review per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600E Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of BRAF V600K Mutation-positive Participants Classified as Confirmed Responders (CR and PR) as Assessed by the Investigator
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
OR is defined as the number of participants with evidence of complete response (CR; disappearance of all extranodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or partial response (PR: at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator per RECIST, Version 1.1.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
Number of Participants With OR Following Cross-over to Trametinib
Tijdsspanne: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
OR is defined as the number of participants with evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 millimeters in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) evaluated by the Investigator in participants following cross-over to Trametinib.
The evaluation was carried out by the Investigator per RECIST, Version 1.1.
Cross-over Population included the subset of participants who were randomized to CT and who elected to cross-over to Trametinib following disease progression on CT.
Only participants who received at least one dose of Trametinib were included in this population.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Duration of Response (DoR) for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the investigator-assessed (INVA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All BRAF V600E Mutation-positive Participants Without a Prior History of Brain Metastases Classified as Confirmed Responders (CR or PR) as Assessed by the Independent Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD (at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation) or death due to any cause.
DoR for the independently-assessed (INDA) response data were summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Investigator Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INVA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Confirmed Responders (CR or PR) as Assessed by the Independent Review
Tijdsspanne: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all target lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR for the INDA response data was summarized per RECIST, Version 1.1.
Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
|
DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator
Tijdsspanne: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions.
Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed.
Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).
NA indicates data was not available.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS Following Cross-over to Trametinib as Assessed by the Investigator
Tijdsspanne: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
PFS is defined as the time from the first dose of cross-over therapy to the first documented occurrence of PD or death.
PFS was summarized per RECIST, Version 1.1.
PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation.
|
Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res. 2016 Feb 1;22(3):567-74. doi: 10.1158/1078-0432.CCR-15-0321. Epub 2015 Oct 7.
- Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.
- Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.
- Latimer NR, Bell H, Abrams KR, Amonkar MM, Casey M. Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy. Cancer Med. 2016 May;5(5):806-15. doi: 10.1002/cam4.643. Epub 2016 Jan 27.
- Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol. 2014 Mar;25(3):700-706. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Neuro-endocriene tumoren
- Nevi en melanomen
- Melanoma
- Moleculaire mechanismen van farmacologische werking
- Enzymremmers
- Antineoplastische middelen
- Proteïnekinaseremmers
- Trametinib
Andere studie-ID-nummers
- 114267
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Melanoma
-
National Taiwan University HospitalOnbekend
-
The Netherlands Cancer InstituteOnbekendStadium IV huidmelanoom | Oog; MelanomaNederland
-
University of AarhusDanish Cancer Society; AmbuFlexVoltooidMelanoma | Kwaliteit van het levenDenemarken
-
Herlev HospitalVoltooidMelanoma | HuidkankerDenemarken
-
Herlev HospitalVoltooidGeïntegreerde basiswetenschap binnen het instructieontwerp van patroonherkenningstraining (AISC-ISF)Melanoma | HuidkankerDenemarken
-
University Medical Center GroningenWervingMelanoma | Hoofd- en nekneoplasmata | MSI-H-kankerNederland
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCVoltooidMelanomaVerenigde Staten
-
Mayo ClinicActief, niet wervendMelanoma | Borstkanker | LymfoedeemVerenigde Staten
-
University of UtahVoltooidMelanoma | JongvolwasseneVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingGlioom | Hematopoietisch en lymfoïde celneoplasma | Kwaadaardig solide neoplasma | Melanoma | SarcoomVerenigde Staten
Klinische onderzoeken op GSK1120212
-
Novartis PharmaceuticalsBeëindigdKankerFrankrijk, Verenigde Staten, Nederland, Canada, Taiwan, Korea, republiek van
-
National Cancer Institute (NCI)Actief, niet wervendGeavanceerd maligne solide neoplasma | Gemetastaseerd maligne solide neoplasma | Gemetastaseerd maligne neoplasma in de lever | Inoperabel solide neoplasmaVerenigde Staten, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupActief, niet wervendJuveniele myelomonocytaire leukemie | Neurofibromatose type 1Verenigde Staten
-
National Cancer Institute (NCI)VoltooidLokaal gevorderd epithelioïde hemangio-endothelioom | Gemetastaseerd epithelioïde hemangio-endothelioom | Inoperabel epithelioïde hemangio-endothelioomVerenigde Staten
-
Jonsson Comprehensive Cancer CenterNovartis; Stand Up To Cancer; Prostate Cancer FoundationActief, niet wervendGemetastaseerd prostaatcarcinoom | Recidiverend prostaatcarcinoom | Stadium IV prostaatkanker | Hormoonresistente prostaatkankerVerenigde Staten
-
National Cancer Institute (NCI)VoltooidRefractair plasmacelmyeloom | Recidiverend plasmacelmyeloomCanada
-
National Cancer Institute (NCI)VoltooidStadium IV oogmelanoom AJCC v7 | Terugkerend oogmelanoomVerenigde Staten, Frankrijk, Verenigd Koninkrijk
-
National Cancer Institute (NCI)BeëindigdTerugkerende volwassen acute myeloïde leukemie | Onbehandelde volwassen acute myeloïde leukemieVerenigde Staten
-
National Cancer Institute (NCI)GlaxoSmithKlineVoltooidStadium IV borstkanker | Recidiverend mammacarcinoom | Invasief mammacarcinoom | Oestrogeenreceptor negatief | HER2/Neu-negatief | Progesteronreceptor negatief | Triple-negatief borstcarcinoomVerenigde Staten
-
National Cancer Institute (NCI)NRG OncologyVoltooidEndometrium Clear Cell Adenocarcinoom | Endometrium adenocarcinoom met gemengde cellen | Endometrium sereus adenocarcinoom | Endometrium ongedifferentieerd carcinoom | Endometrium Adenocarcinoom | Terugkerende baarmoedercorpuskankerVerenigde Staten